Pharmacokinetic and safety of raltegravir in pregnancy

European Journal of Clinical Pharmacology

Volumn 68, Issue 8, 2012, Pages 1231-1232

  Croci, Leonardo ^a   Trezzi, Michele ^b   Allegri, Maria Pia ^a   Carli, Tiziana ^a   Chigiotti, Silvia ^a   Riccardi, Maria Piera ^a   Ricciardi, Barbara ^a   Toti, Mario ^a   Nencioni, Cesira ^a  

^a MISERICORDIA HOSPITAL   (Italy)

^b Ospedale Il Ceppo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR; ETRAVIRINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; CASE REPORT; CESAREAN SECTION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LOW BIRTH WEIGHT; PREGNANCY; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL RELATIONS; PREGNANCY; PYRROLIDINONES; YOUNG ADULT;

EID: 84866483399     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1250-5     Document Type: Letter

References (9)

1. Public Health Service Task Force (2011) Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-InfectedWomen for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.http://AIDSinfo.nih.gov. Accessed 18 October 2011.
2. Public Health Service Task Force (2011) Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. http://AIDSinfo.nih.gov. Accessed 18 October 2011.
3. Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A (2009) Pharmacokinetic variability of antiretroviral drugs and correlationwith virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 64:109-117. doi:10.1093/jac/dkp132.
4. McKeown DA, Rosenvinge M, Donaghy S, Sharland M, Holt DW, Cormack I, Hay P, Sadiq ST (2010) High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 24(15):2416-2418. doi:10.1097/QAD. 0b013e32833d8a50.
5. Jaworsky D, Thompson C, Yudin MH, Bitnun A, Brophy J, Samson L, Antoniou T, Loutfy MR (2010) Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antivir Ther 15:677-680. doi:10.3851/IMP1558.
6. Pinnetti C, Baroncelli S, Villani P, Fantoni M, Tozzi V, De Luca A, Cauda R, Anzidei G, Cusato M, Regazzi M, Floridia M, Tamburrini E (2010) Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 65(9):2050-2052. doi:10.1093/jac/dkq264.
7. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51(18):5843-5855. doi:10.1021/jm800245z.
8. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 35:1657-63. doi:10.1124/dmd.107.016196.
9. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2005) Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27(6-7):602-609. doi:10.1016/j. placenta.2005.05.007.